Clinical Trials Browser

Hodgkin Disease, Leukemia, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases

NCT03467373 2025-01-17

A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

Phase 1 Completed

111 enrolled

Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT03677141 2024-12-18

A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma

Phase 1/2 Completed

117 enrolled 26 charts

Lymphoid

Lymphoma, B-Cell

NCT03671018 2024-11-29

A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma

Phase 1/2 Active not recruiting

422 enrolled

Lymphoid

Lymphoma, B-Cell

NCT05333302 2024-08-28

Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma

Phase 1 Recruiting

10 enrolled

Lymphoid

Burkitt Lymphoma

NCT05219513 2024-08-23

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Phase 1 Terminated

53 enrolled

Lymphoid

Lymphoma, Non-Hodgkin

NCT04313608 2024-03-25

A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma

Phase 1 Completed

23 enrolled 17 charts

Lymphoid

Lymphoma, B-Cell

NCT04657302 2024-01-19

A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase 1 Completed

30 enrolled

Lymphoid

Lymphoma

NCT05833763 2024-01-08

GOlDiLOX

Phase 2 Recruiting

42 enrolled

Lymphoid

Lymphoma, Mantle-Cell

NCT03467256 2023-02-24

CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL

Phase 1/2 Unknown

18 enrolled

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03588936 2021-10-11

Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant

Phase 1 Terminated

2 enrolled

LymphoidMyeloid

Lymphoma, Myelodysplastic Syndromes

NCT02906371 2021-07-02

Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome

Phase 1 Completed

80 enrolled

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02336048 2021-04-08

A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities

Phase 1 Terminated

38 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01441063 2020-10-27

Tocilizumab for KSHV-Associated Multicentric Castleman Disease

Phase 2 Completed

8 enrolled 18 charts

LymphoidSarcoma

Multi-centric Castleman's Disease, Acquired Immunodeficiency Syndrome, Castleman Disease, Sarcoma, Kaposi